Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.

Dhall D, Mertens R, Bresee C, Parakh R, Wang HL, Li M, Dhall G, Colquhoun SD, Ines D, Chung F, Yu R, Nissen NN, Wolin E.

Hum Pathol. 2012 Apr;43(4):489-95. doi: 10.1016/j.humpath.2011.06.011. Epub 2011 Sep 19.

PMID:
21937080
2.
3.

Nuclear markers (star volume, mitotic index, AgNOR and Ki-67) of the primary tumor and its metastasis in non-small cell lung carcinomas.

Matheus RS, Bernardi Fdel C, Gallo CP, da Silva AP, Rodrigues OR, Capelozzi M, Lopes A, Fenezelian S, Saldiva PH, Capelozzi VL.

Pathol Res Pract. 2004;200(1):13-23.

PMID:
15157046
4.

Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors.

Walts AE, Ines D, Marchevsky AM.

Mod Pathol. 2012 Sep;25(9):1258-64. doi: 10.1038/modpathol.2012.81. Epub 2012 May 11.

5.

Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.

Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.

Anticancer Res. 2002 Nov-Dec;22(6B):3759-64.

PMID:
12552989
6.

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.

Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC.

Cancer. 2005 Oct 15;104(8):1590-602.

7.

MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors.

Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP.

Cancer. 2000 Jun 1;88(11):2598-605.

PMID:
10861439
8.

Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases.

Burke AP, Thomas RM, Elsayed AM, Sobin LH.

Cancer. 1997 Mar 15;79(6):1086-93.

PMID:
9070484
9.

Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors.

Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Têtu B, Meyer F, Fradet Y.

Hum Pathol. 1999 Nov;30(11):1350-5.

PMID:
10571516
10.

Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices.

Remes SM, Tuominen VJ, Helin H, Isola J, Arola J.

Am J Surg Pathol. 2012 Sep;36(9):1359-63. doi: 10.1097/PAS.0b013e3182632038.

PMID:
22895268
11.

Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS.

Cancer. 2005 Jun 15;103(12):2517-25.

12.

Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival.

Voland P, Besig S, Rad R, Braun T, Baur DM, Perren A, Langer R, Höfler H, Prinz C.

Neuroendocrinology. 2009;89(1):66-78. doi: 10.1159/000151482. Epub 2008 Aug 18.

13.

Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.

Sittel C, Eckel HE, Damm M, von Pritzbuer E, Kvasnicka HM.

Laryngoscope. 2000 Jun;110(6):1012-7.

PMID:
10852523
14.

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.

Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M.

Mod Pathol. 2010 Jun;23(6):824-33. doi: 10.1038/modpathol.2010.58. Epub 2010 Mar 19.

15.

Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer.

Komaki R, Milas L, Ro JY, Fujii T, Perkins P, Allen P, Sikes CR, Mountain CF, Ordonez NG.

Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):787-96.

PMID:
9531362
16.

Ki-67 from clinically and histologically "normal" distant mucosa as prognostic marker in early-stage (T1-T2N0) oral squamous cell carcinoma: a prospective study.

Montebugnoli L, Gissi DB, Badiali G, Marchetti C, Cervellati F, Farnedi A, Foschini MP.

J Oral Maxillofac Surg. 2011 Oct;69(10):2579-84. doi: 10.1016/j.joms.2010.10.041. Epub 2011 Feb 3.

PMID:
21292374
17.

Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.

Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, Shah JP, Singh B, Ghossein RA.

Cancer. 2006 Mar 15;106(6):1286-95.

18.

Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index.

Lee HE, Mounajjed T, Erickson LA, Wu TT.

Endocr Pathol. 2016 Sep;27(3):259-67. doi: 10.1007/s12022-016-9443-6.

PMID:
27306997
19.

Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.

Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A.

Neuropathology. 2007 Apr;27(2):114-20.

PMID:
17494511
20.

Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.

Morin E, Cheng S, Mete O, Serra S, Araujo PB, Temple S, Cleary S, Gallinger S, Greig PD, McGilvray I, Wei A, Asa SL, Ezzat S.

Cancer Med. 2013 Oct;2(5):701-11. doi: 10.1002/cam4.96. Epub 2013 Aug 6.

Supplemental Content

Support Center